HFA-ICOS Cardio-Oncology Risk Estimator
Use this tool to estimate baseline cardiovascular risk before potentially cardiotoxic cancer therapy. It follows an HFA-ICOS-style educational scoring model and is not a diagnosis tool.
Medical disclaimer: This calculator is educational and does not replace physician judgment, guideline-based clinical evaluation, or individualized oncology/cardiology care.
What is the HFA-ICOS risk calculator?
The HFA-ICOS framework is used in cardio-oncology to stratify a patient’s risk of cancer therapy–related cardiovascular toxicity before treatment starts. In practical terms, clinicians want to know: “How likely is this person to develop heart complications during or after cancer treatment, and how aggressively should we monitor and protect them?”
This page gives you a structured, point-based estimator inspired by common HFA-ICOS principles: baseline heart function, pre-existing cardiovascular disease, and treatment-specific exposure (for example anthracyclines, HER2 therapies, and chest radiation).
How this calculator estimates risk
1) Baseline patient factors
Age, left ventricular ejection fraction (LVEF), and cardiometabolic burden (hypertension, diabetes, kidney disease, smoking, obesity) all influence reserve capacity. Lower reserve means less tolerance for cardiotoxic stress.
2) Prior cardiovascular disease
Existing heart failure, cardiomyopathy, prior myocardial infarction, or cerebrovascular disease can move a patient quickly into a higher-risk category. These conditions often indicate underlying myocardial vulnerability.
3) Planned cancer therapy exposure
Some therapies carry known cardiovascular risk profiles. Cumulative anthracycline dose, HER2-targeted treatment, VEGF pathway inhibitors, and heart-exposed radiation may increase cardiotoxicity risk, especially when combined.
4) Biomarker signal
Elevated baseline troponin or natriuretic peptide can indicate subclinical myocardial stress and may justify tighter surveillance during treatment.
Interpreting your score
- Low risk: routine oncology care with standard cardiac follow-up.
- Moderate risk: consider a tailored monitoring plan and early prevention discussion.
- High risk: cardio-oncology co-management is usually appropriate; serial imaging/biomarkers often needed.
- Very high risk: multidisciplinary planning before treatment is strongly recommended, including preventive strategies and close monitoring.
Suggested monitoring concepts by category
Low to moderate risk
- Baseline echocardiogram and ECG.
- Interval reassessment based on regimen intensity.
- Lifestyle optimization: blood pressure, glucose, exercise, smoking cessation.
High to very high risk
- Baseline cardio-oncology consultation.
- Serial echocardiography (including strain when available).
- Periodic troponin/BNP monitoring if clinically indicated.
- Discussion of cardioprotective therapies and regimen alternatives where appropriate.
Important limitations
Any point calculator simplifies reality. True risk depends on cancer type, cumulative treatment exposure, time course, prior radiation fields, genetic predisposition, and real-time treatment response. This tool should be used for education and planning conversations, not for independent medical decision-making.
Frequently asked questions
Is this an official diagnostic tool?
No. It is a practical educational estimator aligned with cardio-oncology risk concepts. Formal clinical decisions should use institutional protocols and specialist input.
Does a high score mean treatment should stop?
Not necessarily. High risk usually means better preparation, tighter surveillance, and coordinated care—not automatic treatment cancellation.
Can risk be lowered?
Often yes. Optimizing blood pressure, glycemic control, smoking cessation, weight, and early cardiology involvement can reduce preventable complications.
Bottom line
A structured HFA-ICOS risk approach helps teams match treatment intensity with cardiac safety planning. Use this calculator to support informed conversations about baseline risk, monitoring frequency, and proactive cardio-oncology care.